BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
initiated coverage of Invivyd with a Buy rating and $10 price target. BTIG maintained this stance on Invivyd, citing the company's established expertise in antibody production. The firm informed investors that VYD2311's market potential far exceeds that of Pemgarda, which positions the stock for significant growth. Additionally, on December 23, Invivyd announced two major regulatory and clinical milestones for VYD2311, which is its investigational monoclonal antibody/mAb designed as a vaccine alternative for COVID-19 prevention. The US FDA granted Fast Track designation to VYD2311 for preventing COVID-19 in individuals with underlying risk factors for severe disease. Simultaneously, Invivyd Inc. (NASDAQ:IVVD) initiated DECLARATION, a pivotal Phase 3, randomized, triple-blind, placebo-controlled clinical trial. This BLA-enabling study will evaluate the safety and efficacy of VYD2311 in preventing symptomatic COVID-19 across a broad population of ~1,770 adults and adolescents. The t
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- ?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]Yahoo! Finance
- Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]Yahoo! Finance
- Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]Yahoo! Finance
- Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business HighlightsGlobeNewswire
- Does Invivyd's (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 1/8/26 - Form 8-K
- 12/29/25 - Form SCHEDULE
- 12/29/25 - Form EFFECT
- IVVD's page on the SEC website